• Immunotherapy for malignant glioma is complicated by several factors that may limit the therapeutic efficacy of monotherapies: (i) gliomas are characterized by a high degree of inter-tumor and intra-tumor cellular and molecular heterogeneity; (ii) gliomas have been shown to induce immunosuppression through secreted factors, expression of immunosuppressive checkpoints, and infiltration of immunosuppressive cells.
Introduction
Gliomas are highly invasive tumors which often occur in the cerebral hemispheres 1 .
Glioblastoma Multiforme (GBM), the most common and aggressive form of glioma, has a 5-year survival rate of about 5% 2 , creating a need for aggressive and effective therapies. Current standard of care includes surgical resection followed by radiotherapy and the alkylating agent temozolomide (TMZ) 3 . However, surgical resection is limited by the diffuse, infiltrative nature of these tumors, and median survival following surgery, radiotherapy, and TMZ remains dismal 3 .
The development of immunotherapies which target unique features of glioma may significantly improve therapeutic outcomes. It has been extensively demonstrated that it is not possible to mount an effective adaptive immune response against antigens located within the brain parenchyma [4] [5] [6] [7] . However, research from our group and others has established that the central nervous system is not an immune-privileged site as previously thought [8] [9] [10] [11] . Antigen presenting cells (APCs) are indeed present in the normal brain 12 , albeit at very low levels. Immune cells can traffic from the CNS to the draining cervical lymph nodes 13 , and the BBB is permeable to immune cells under conditions of inflammation 14 , opening the door to effective immunotherapies for tumors located within the brain. One main hurdle that needs to be overcome is the highly immunosuppressive nature of the tumor microenvironment 14, 15 , which hampers the efficacy of immunotherapies.
Molecular heterogeneity in glioma
Recent advances in molecular characterization of gliomas have allowed for higher resolution classification, facilitating the development of precision immunotherapies or combinations of immunotherapies for GBM. Traditional histopathological methods of diagnosis rely on morphological classification of gliomas as astrocytomas, oligodendrogliomas, or oligoastrocytomas, a process which is complicated by morphological ambiguity and interobserver variability 16 . The new 2016 WHO classification of CNS tumors incorporates both histopathological features and molecular markers into its updated classification scheme, increasing objectivity of classification and homogeneity of diagnostic groupings 17 . The 2016 WHO classification distinguishes primary and secondary GBM based on IDH mutation status.
While IDH wild type and IDH mutant tumors appear histologically similar, they arise from distinct cells of origin and likely represent separate disease entities 18 . Primary GBMs, which arise de novo mostly in elderly patients, are defined by wild type IDH1 status, while secondary GBMs, which usually occur in younger patients and are associated with a more favorable prognosis, display mutant IDH1
19
. Pediatric gliomas are characterized by the presence of PDGFR amplification 20 and H3F3A mutation 21, 22 . Other molecular markers with prognostic value are methylation of the MGMT gene and codeletion of chromosome arms 1p and 19q, which are both independently associated with favorable clinical prognosis 23 , and ATRX mutations, which result in greater responsiveness to double stranded DNA-damaging agents in preclinical studies 24 .
Large scale clustering of recurrent genomic alterations in GBM into proneural, neural, classical, and mesenchymal subtypes reveals differences in treatment efficacy of chemotherapy and radiotherapy 25 . However, clinically relevant molecular characterization of tumors is complicated by the heterogeneity of molecular markers within a single tumor. Recent studies reveal that individual GBMs contain a mixture of cells corresponding to different subtypes;
genetic signatures from cells in one tumor could be classified into more than one subtype in 5 out of 5 tumors sampled in one study 26 and 6 out of 10 tumors sampled in another 27 . The striking diversity of tumor cells across different gliomas and within a particular tumor suggests that single therapies are less likely to be effective. Furthermore, treatment using a therapy which targets a single tumor specific antigen might eliminate highly antigenic tumor cells, applying a selective pressure in favor of variants which escape the immune system through poor antigenicity 28, 29 . A trial of the EGFRvIII peptide vaccine in patients with EGFRvIII-expressing GBM revealed that 82% of recurrent tumors had lost EGFRvIII expression 29 , suggesting that tumors may lose their antigenic epitopes over time.
Immunosuppression in glioma
The success of immunotherapies may be limited by a number of immunosuppressive mechanisms employed by GBM; understanding and targeting these mechanisms will likely broaden the therapeutic potential of immunotherapies. Glioma cells overexpress secreted immunosuppressive factors including TGF-β, IL-10, and VEGF (which limits antitumor immunity through defective dendritic cell (DC) maturation in addition to its role in neovascularization) 30, 31 . Glioma-secreted Indolamine 2,3 Dioxygenase 1 (IDO) is a tryptophanmetabolizing enzyme that inhibits effector T cell function and increases the recruitment of immunosuppressive regulatory T cells (T regs ) 32 . It has been found that T regs , which physiologically inhibit T cell activation to prevent autoimmunity, represent an increased fraction of the CD4+ T cell population in patients with malignant glioma, resulting in immunosuppression 33 . In addition to T regs, gliomas have increased infiltration of other immunosuppressive cells such as tumor associated macrophages (TAMs), which enhance tumor invasiveness and secrete immunosuppressive cytokines 34 , and myeloid-derived suppressor cells (MDSCs), which suppress T cell functions and promote the expansion of T regs 35, 36 . Cell surface molecules can further dampen antitumor immunity; GBM cells which express FasL induce apoptosis in T lymphocytes which express Fas 37 . Gliomas also strongly express B7-H1, or PDL1
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, inhibiting CD4+ and CD8+ T cell activation and mediating T cell exhaustion through the activation of Programmed Cell Death Protein 1 (PD-1) 39 . This process of T cell exhaustion results in decreased cytokine expression and effector function and upregulation of multiple immunosuppressive markers such as immunological checkpoints PD-1, Tim-3, and LAG-3 40 . Cytotoxic T lymphocyte antigen 4 (CTLA4), a marker expressed on activated T cells and T regs 41, 42 binds with high affinity to CD80 and CD86 receptors, blocking costimulatory signaling for T cell activation [43] [44] [45] . Because these markers limit the ability of the immune system to mount a successful antitumor response, and therapeutic strategies using blocking antibodies that target these proteins have proven efficacious for other tumors, such as melanoma, immunosuppressive checkpoints are attractive targets for GBM immunotherapy.
Single immunotherapies for glioma
Several approaches to immunotherapy for glioma are currently being tested, including immunosuppressive checkpoint blockade, immunostimulatory gene therapy, active immunotherapy through vaccination, passive antibody therapy, and adoptive immunotherapy through T cell transfer or CAR T cells [46] [47] [48] [49] patient-derived DCs were pulsed with the same set of six synthetic peptides included in the ICT-107 vaccine (HER2, TRP-2, gp100, MAGE-1, IL13Rα2 and AIM-2) 58 . Treatment efficacy was compared with placebo control, demonstrating limited clinical benefit.
Combination immunotherapeutic strategies for glioma
Combinations of immunotherapies may improve upon single immunotherapies through is the occurrence of treatment-related adverse events; the study of ipilimumab and nivolumab in patients with melanoma revealed treatment-related adverse events including rash, pruritus, fatigue, and diarrhea in 93% of patients who received concurrent treatment, and serious adverse events including hepatic, gastrointestinal, and renal events in 49% of patients who received concurrent treatment 60 . Although the study reports that treatment-related adverse events were generally manageable with immunosuppressants, these findings warrant further exploration into strategies which limit treatment-related adverse events.
Checkpoint inhibitors combined with other immunotherapies
Immune checkpoint blockade therapy may also increase the efficacy of vaccination and . These studies indicate that activation of the immune system in combination with strategies which limit barriers to immune function upon activation may be promising strategies for clinical trials in the future.
Combination strategies utilizing vaccination therapy 3.4.1 Vaccination combined with immune stimulatory adjuvants
Immune stimulatory adjuvants such as GM-CSF and TLR agonists have been used to enhance vaccination-induced immune responses. In a phase I study of the IMA950 vaccine, a peptide vaccine containing 11 GBM-associated peptides, with GM-CSF, a cytokine which stimulates DC maturation, in newly diagnosed GBM patients, 90% of patients had a CD8+ T-cell immune response to at least one peptide, but the amplitude was low ISA-51 and GM-CSF has been shown to induce cytotoxic immune reactions in both preclinical 90 and clinical studies [91] [92] [93] .
Vaccination combined with other immunotherapies
One option for combination therapy that is under investigation in multiple solid tumors is the use of DC vaccination alongside adoptive T cell transfer. This concept derives from the principle that while DC vaccine monotherapy generally has acceptable toxicity, the immune response is often gradual and clinical efficacy frequently sub-optimal 46, 72, 94 . Similarly, efforts to perform isolated adoptive T cell transfer for solid tumors often result in a rapid decrease in the persistence of the infused T-cells 94 . Therefore early work combining these therapies has involved optimizing the time interval between DC vaccination and T cell transfer. In preclinical work performed in adenocarcinoma models, it was shown that vaccination with CEApeptide pulsed DCs within one day of adoptive transfer of CEA-specific T cells resulted in synergistic tumor killing 94 . This result was not seen when the DC vaccine was administered even three days after T cell transfer 94 . Similarly, the combination of tumor antigen loaded DCs with lymph node derived T cells has proven efficacious in pre-clinical models of mammary carcinoma and melanoma 95, 96 . The feasibility and safety of this approach was demonstrated in a Phase I clinical trial of patients with metastatic melanoma 97 .
While not yet tested specifically in human GBM patients, this approach is currently being studied in a clinical trial in pediatric patients with refractory medulloblastoma (NCT01326104). In this trial, DCs and autologous lymphocytes are loaded with total tumor RNA (TTRNA). The lymphocytes are then infused intravenously along with multiple doses of intradermal DC vaccination.
Vaccination therapies for GBM have also been combined with anti-angiogenic monoclonal antibody therapy. Bevacizumab is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting new blood vessel formation. GBM is a highly vascular tumor and strongly expresses VEGF, prompting initial enthusiasm for its use as a therapeutic agent 98, 99 . Unfortunately, bevacizumab therapy has not improved overall survival in GBM, despite some evidence of providing improved progression-free survival 99 . Combining anti-angiogenic therapy with immune-based therapies may have synergistic impact; antiangiogenic therapy normalizes the tumor vasculature, promoting better infiltration of immune cells into the tumor mass and resulting in immune-mediated tumor death 100, 101 . A current trial is investigating whether the combination of bevacizumab and Rindopepimut (a vaccine comprising the EGFRvIII-specific peptide sequence conjugated to keyhole limpet hemocyanin (KLH), a carrier protein) will prove efficacious in relapsed EGFRvIII-positive GBM (NCT01498328).
Another trial in relapsed GBM is exploring the use of bevacizumab in combination with a vaccine derived from autologous tumor heat shock protein-peptide complexes which deliver tumor antigens to DCs (NCT01814813) 102 .
Chemotherapy and immunotherapy
Standard of care TMZ chemotherapy has been shown to cause profound lymphopenia and . As oncolytic virotherapies improve in cytotoxic efficacy and we begin to elucidate the role of the host immune response in oncolytic virotherapy it may be possible to design combinations which minimize opposing immune effects.
Conclusion
Growing provides a compelling rationale for testing these combined therapeutic strategies in GBM patients.
Expert opinion
Glioma is one of the most challenging to treat human cancers, and patients have a dismal prognosis in spite of improved standard of care, which includes surgery, radiation and chemotherapy 2, 3 . Several compounding factors complicate the treatment of this primary brain cancer. Most notably, at the time of diagnosis the tumor is already very large (due to the lack of early symptoms), highly invasive, and is histologically and molecularly heterogeneous With many of the above mentioned approaches, pre-clinical efficacy data generated from animal models of GBM has not been able to predict efficacy in human patients. There are many reasons for this, but the most critical include: the use of flank tumor models that do not mimic the brain anatomical and physiological microenvironment, the use of homogeneous tumor cells over-expressing the single antigen of choice, treatment of very small tumors which are not representative of the clinical scenario, lack of testing in models of GBM recurrence, and using statistically significant, albeit biologically small effect-size differences in median survival as an indication that a particular therapeutic approach could be successful in Phase I clinical trials. The field is now beginning to address some of these issues, with the development of more stringent models that enable testing of experimental immunotherapies in large and heterogeneous brain tumor models, using models of GBM recurrence, and working towards treatments that start at the time the animal becomes symptomatic due to tumor burden. In addition, the consensus is that due to the highly heterogeneous nature and the rapid rate of mutation of GBM tumor cells, the use of a single therapeutic modality will not prove to be efficacious against this disease 26, 27 .
Thus, several groups, including our own, are moving towards combination therapies. To that effect, our group has pioneered a gene therapy-mediated combined conditional cytotoxic immune stimulatory strategy that is currently being tested in human patients with GBM. This combination 
